Avascular Necrosis Market, by Type (Trauma Related Avascular Necrosis, Non-Trauma Related Avascular Necrosis), by Treatment (Drug Based, Surgery Based {Core Decompression Surgery, Osteotomy, Bone Graft, And Total Joint Replacement}), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast to 2026

  • Published On : Oct 2018 |
  • Pages : 147 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Avascular Necrosis Market – Insights

Avascular necrosis (AVN) also termed as osteonecrosis, or aseptic necrosis, or ischemic bone necrosis, a condition resulting in the death of bone cells due to loss of blood supply. It often leads to collapse of the joint surface and subsequent arthritis due to an irregular joint surface.  Avascular necrosis affects the ends (epiphysis) of long bones such as femur, upper humerus, and bones of ankle joint. Usually it develops due to combination of various factors including metabolic, genetic, increased alcohol consumption, smoking, and other diseases.

An X-ray is generally used to diagnose cause of joint pain. However, magnetic resonance imaging (MRI), is the most sensitive method for diagnosing avascular necrosis in early stages. Unlike X-rays, bone scans, and computed/computerized tomography (CT) scans, MRI detects chemical changes in bone marrow and shows avascular necrosis in its earliest stages.

Nonsurgical treatment options for avascular necrosis such as anti-inflammatory medications, activity changes, and crutches can help relieve pain and slow progression of the disease. Surgical treatment include core decompression, bone and cartilage grafting, and total hip replacement. Based on the cause, avascular necrosis can be classified as traumatic and non-traumatic avascular necrosis.

According to the Science Direct Journal 2010 report, traumatic injury such as ankle sprain, fracture and joint dislocation is the most common cause of AVN, which can occur eight hours after disruption to the blood supply. Non-traumatic avascular necrosis occurs usually at young age and its causes include chronic liver disease, corticosteroids, decompression sickness, fat embolism syndrome, Gaucher disease, gout, hyperlipidaemia, haemoglobinopathy, metabolic bone disease, systemic chemotherapy systemic lupus erythematosus, and alcoholism among others.

The global avascular necrosis market size was valued at US$ 512.9 million in 2017, and is expected to witness a CAGR of 6.0% over the forecast period (2018 – 2026).

Global Avascular Necrosis Market Value (US$ Mn) & Y-o-Y Growth (%)

Avascular Necrosis  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2018)

Increasing Alcohol Consumption and Use of Corticosteroids are Expected to Drive Growth of the Avascular Necrosis Market

Excessive alcohol consumption and long-term, high dose systemic corticosteroid use are the major risk factors for avascular necrosis. According to World Journal of Orthopedics, 2015, avascular necrosis usually affects people between 30 and 50 years of age. Also, from the same source, about 10,000 to 20,000 people develop osteonecrosis each year in the U.S. According to National Organization for Rare Disorders’ 2015 data, alcohol consumption and corticosteroid use affects about 30% and 35% of all people with non-traumatic avascular necrosis, respectively across the globe.

Other risk factors or conditions associated with non-traumatic osteonecrosis include autoimmune disease, cancer, decompression disease (Caisson disease), Gaucher disease, pancreatitis, HIV infection, and blood disorders such as sickle cell disease. Certain medical treatments including radiation therapy and chemotherapy can also cause osteonecrosis. Moreover, people who have undergone organ transplants are at high developmental risk of osteonecrosis.

Technological advancement in therapies for avascular necrosis such as Advanced Therapy Medicinal Products (ATMPs) is expected to boost avascular necrosis market. Advanced Therapy Medicinal Products is a class of innovative therapies that comprises of gene therapy, somatic cell therapy, and tissue-engineered products.

Avascular Necrosis Market Restraints

High cost of surgical treatments and delay in diagnosis due to asymptomatic nature of this condition at early stage are the major restraining factors for avascular necrosis market growth. For instance, according to Blue Cross Blue Shield of North Carolina, a total hip replacement procedure usually cost between US$ 31,839 and US$ 44,816, with an average cost of US$ 39,299.

Avascular Necrosis Market - Regional Insights

On the basis of region, the global avascular necrosis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to generate a significant revenue share in global avascular necrosis market during the forecast period due to increasing prevalence of avascular necrosis and prior Food and Drug Administration (FDA) approval for the new avascular necrosis treatments in the region. For instance, according to National Center for Biotechnology Information (NCBI), 2015, about 20,000 to 30,000 new patients are diagnosed with avascular necrosis every year in the U.S.

Asia Pacific avascular necrosis market is expected to foresee highest growth rate during the forecast period, owing to increase in development activities for the treatment of avascular necrosis by various key players in this region. For instance, in 2017, Asahi Kasei Corporation and Bone Therapeutics signed a license agreement for the development and commercialization of PREOB in Japan. PREOB is an autologous osteoblastic cell therapy product derived from ex vivo cultured bone marrow cells of the patients.

Global Avascular Necrosis Market Share 2017 (%), By Region

       Avascular Necrosis  | Coherent Market Insights  

 Source: Coherent Market Insights Analysis (2018)

Avascular Necrosis Market - Competitive Landscape

Key players operating in the global avascular necrosis market include Bone Therapeutics, Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon Inc., Eli Lilly and Company, Grifols SA, Integra LifeSciences Corporation, K-Stemcell Co Ltd., Medtronic Plc, Merck KGaA, Pfizer Inc., Sanofi SA, Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings. Manufacturers are focusing on advancements in treatment technologies such as gene therapy and stem cell-based treatment for avascular necrosis.

Avascular necrosis (AVN), also called osteonecrosis, ischemic bone necrosis, or aseptic necrosis, is a condition that occurs due to loss of blood flow to the bone. The condition mostly occurs in the hip however, other common sites include ankle, knee, and shoulder. Individuals between the age of 20 and 50 years are more susceptible to avascular necrosis. Most cases of avascular necrosis occur due to an underlying health problem or injury. Moreover, factors such as increased intake of corticosteroids and alcohol may cause fatty substances to build in the blood vessels and decrease the blood supply to the bones, eventually causing avascular necrosis. Treatment for this condition depends on a number of factors, including age, disease stage, location, and amount of bone damage.

Market Dynamics

Growth of avascular necrosis market is primarily driven by factors such as increasing incidence of avascular necrosis, high demand for non-invasive treatment, and increasing dependence on surgery to cure avascular necrosis. According to Bone Therapeutics report in 2017, around 170,000 patients were suffering from avascular necrosis in the U.S., Europe, and Japan. Moreover, side effects from various medicines taken during cancer, HIV/AIDS, osteoporosis, osteoarthritis, blood disorders, or medical treatment such as chemotherapy, radiation therapy, high-dosage of steroids, and organ transplants can increase chances of developing avascular necrosis. However, delay in diagnosis due to asymptomatic nature of this condition at early stage and high cost of surgical treatments for avascular necrosis are the major factors hampering growth of the avascular necrosis market.

Key features of the study:

  • This report provides in-depth analysis of the avascular necrosis market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global avascular necrosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Bone Therapeutics, Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon Inc., Eli Lilly and Company, Grifols SA, Integra LifeSciences Corporation, K-Stemcell Co Ltd., Medtronic Plc, Merck KGaA, Pfizer Inc., Sanofi SA, Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global avascular necrosis market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for avascular necrosis products, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Avascular Necrosis Market, By Type:
    • Trauma Related Avascular Necrosis
    • Non-Trauma Related Avascular Necrosis
  • Global Avascular Necrosis Market, By Treatment:
    • Drug Based
    • Surgery
      • Core decompression surgery
      • Osteotomy
      • Bone graft
      • Total joint replacement
  • Global Avascular Necrosis Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Type:
        • Trauma  Related  Avascular  Necrosis
        • Non-Trauma  Related  Avascular  Necrosis
      • By Treatment:
        • Drug Based
        • Surgery
          • Core decompression surgery
          • Osteotomy
          • Bone graft
          • Total joint replacement
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Type:
        • Trauma  Related  Avascular  Necrosis
        • Non-Trauma  Related  Avascular  Necrosis
      • By Treatment:
        • Drug Based
        • Surgery
          • Core decompression surgery
          • Osteotomy
          • Bone graft
          • Total joint replacement
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Type:
        • Trauma  Related  Avascular  Necrosis
        • Non-Trauma  Related  Avascular  Necrosis
      • By Treatment:
        • Drug Based
        • Surgery
          • Core decompression surgery
          • Osteotomy
          • Bone graft
          • Total joint replacement
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Type:
        • Trauma  Related  Avascular  Necrosis
        • Non-Trauma  Related  Avascular  Necrosis
      • By Treatment:
        • Drug Based
        • Surgery
          • Core decompression surgery
          • Osteotomy
          • Bone graft
          • Total joint replacement
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Type:
        • Trauma  Related  Avascular  Necrosis
        • Non-Trauma  Related  Avascular  Necrosis
      • By Treatment:
        • Drug Based
        • Surgery
          • Core decompression surgery
          • Osteotomy
          • Bone graft
          • Total joint replacement
    • Africa
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
      • By Type:
        • Trauma  Related  Avascular  Necrosis
        • Non-Trauma  Related  Avascular  Necrosis
      • By Treatment:
        • Drug Based
        • Surgery
          • Core decompression surgery
          • Osteotomy
          • Bone graft
          • Total joint replacement
  • Company Profiles
    • Bone Therapeutics*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Boehringer Ingelheim GmbH
    • Bayer AG
    • Enzo Biochem Inc.
    • Ethicon Inc.
    • Eli Lilly and Company
    • Grifols SA
    • Integra LifeSciences Corporation
    • K-Stemcell Co Ltd.
    • Medtronic Plc
    • Merck KGaA
    • Pfizer Inc.
    • Sanofi SA
    • Stryker Corporation
    • Wright Medical Group N.V.
    • Zimmer Biomet Holdings

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Treatment
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Technological Advancements
    • Epidemiology Analysis
    • PEST Analysis
    • Pipeline Analysis
  4. Global Avascular Necrosis Market, By Type, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2016 – 2026
      • Segment Trends
    • Trauma  Related  Avascular  Necrosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Non-Trauma  Related  Avascular  Necrosis
      • Introduction  
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  5. Global Avascular Necrosis Market, By Treatment, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2016 – 2026
      • Segment Trends
    • Drug-Based
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Surgery-Based
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
        • Core decompression surgery
        • Osteotomy
        • Bone graft
        • Total joint replacement
  6. Global Avascular Necrosis Market, By Region, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2016 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Treatment, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Treatment, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Treatment, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Treatment, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Treatment, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Northern Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Treatment, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Bone Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Enzo Biochem Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Ethicon Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Grifols SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Integra LifeSciences Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • K-Stemcell Co Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Medtronic Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck KGaA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Stryker Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Wright Medical Group N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zimmer Biomet Holdings
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 17 market data tables and 21 figures on "Avascular Necrosis Market” - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]coherentmarketinsights.com

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.